Proteomics

$60,917P30FY2022CANIH

Stanford University, Stanford CA

Investigators

Linked publications, trials & patents

Paper 39574895 Paper 39534431 Paper 39506045 Paper 39378093 Paper 39257774 Paper 39179931 Paper 39163262 Paper 39132489 Paper 39042439 Paper 38997156 Paper 38996463 Paper 38987048 Paper 38968138 Paper 38838737 Paper 38810650 Paper 38746193 Paper 38563850 Paper 38496616 Paper 38496500 Paper 38408498 Paper 38387457 Paper 38278150 Paper 38273211 Paper 38262408 Paper 38260330 Paper 38200310 Paper 38154193 Paper 38096469 Paper 37963187 Paper 37917579 Paper 37882771 Paper 37812494 Paper 37743567 Paper 37667254 Paper 37662553 Paper 37534980 Paper 37532139 Paper 37527449 Paper 37398193 Paper 37244414 Paper 37196642 Paper 37184546 Paper 37162847 Paper 36999999 Paper 36993756 Paper 36813894 Paper 36747642 Paper 36734849 Paper 36729432 Paper 36729074 Paper 36719070 Paper 36717409 Paper 36711732 Paper 36701540 Paper 36652552 Paper 36640300 Paper 36635501 Paper 36624348 Trial NCT05220254 Trial NCT03733210 Trial NCT03405142 Trial NCT03241940 Trial NCT03179449 Trial NCT02855086 Trial NCT02805075 Trial NCT02762266 Trial NCT02736578 Trial NCT02735356 Trial NCT02699723 Trial NCT02695628 Trial NCT02690948 Trial NCT02683824 Trial NCT02635074 Trial NCT02624518 Trial NCT02599194 Trial NCT02581787 Trial NCT02488070 Trial NCT02440308 Trial NCT02432118 Trial NCT02429804 Trial NCT02415608 Trial NCT02401347 Trial NCT02215928 Trial NCT02210858 Trial NCT02203565 Trial NCT02184533 Trial NCT02175745 Trial NCT02166983 Trial NCT02058550 Trial NCT02030405 Trial NCT02019069 Trial NCT01977677 Trial NCT01943188 Trial NCT01928030 Trial NCT01926990 Trial NCT01908166 Trial NCT01904643 Trial NCT01898403 Trial NCT01893892 Trial NCT01868503

Abstract

PROJECT SUMMARY The Proteomics Shared Resource (P-SR) is focused on fostering high-impact cancer-relevant research by providing SCI members with access to state-of-the-art, user-friendly mass spectrometry-based resources and expertise. The P-SR operates 15 mass spectrometer systems that serve ~60 SCI researchers annually. Research support goals are accomplished via the following technical capabilities (1) full-service research partnership from experiment design through sample preparation and mass spectrometric analysis to data analysis; (2) broad-spectrum proteomic support from pilot discovery through complex quantitative assays; (3) customizable quantitative small molecule and clinical scale proteomic assays, taking advantage of modern advances in multiplexing and targeted techniques; (4) intact protein characterization, including antibodies and antibody-drug conjugates; (5) open access walk-up instrumentation and hands-on experience; and (6) online and in-person education, training, and network-building opportunities. These technical capabilities are foundational to numerous scientific areas, such as (1) discovering relevant molecular targets in cancer; (2) providing accurate, orthogonal means of validating research findings from genomic and transcriptomic analyses at the protein level; (3) supporting cancer drug discovery efforts with pharmacokinetics and metabolism analytics; and (4) investigating biological pathways and signaling mechanisms relevant to cancer, both for target and biomarker discovery. Since the last review, the P-SR has continued to acquire new high-end instrumentation, including a Thermo Scientific Q Exactive HF-X and a Waters Xevo TQ-XS. Members of all programs use the P-SR, with the heaviest use coming from the Cancer Biology and Cancer Stem Cells and Cancer Therapeutics programs. In 2020, 41% of users were SCI investigators. The P-SR contributed to 10 cancer-focused publications (5 high-impact). The annual budget of the P-SR is $1,547,560, yet the CCSG request is $70,495. Accordingly, the P-SR leverages extensive institutional support and seeks only 5% from CCSG funds.

View original record on NIH RePORTER →